Hospital Universitari Vall dHebron; Oncology
Barcelona, Spain
Hospital in Barcelona
Passeig de la Vall d'Hebron, 119, 08035 Barcelona
1,146 Beds
About Hospital Universitari Vall dHebron; Oncology
The Vall d'Hebron University Hospital is a public and university affiliated hospital founded in 1955. It belongs to the Catalan Health Institute and is the hospital complex with the highest volume of interventions in Catalonia, Spain.
There are 1,146 beds in Hospital Universitari Vall dHebron; Oncology.
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
16
EMD Serono Research & Development Institute, Inc.
8
Pfizer
2
Genentech, Inc.
1
Merck KGaA, Darmstadt, Germany
1
Clinical Trials at Hospital Universitari Vall dHebron; Oncology
During the past decade, Hospital Universitari Vall dHebron; Oncology conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 10 clinical trials were completed, i.e. on
average, 35.7% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 10 clinical trials were completed. i.e. 111.1%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
Dose-Escalation Study Of Palbociclib + Nab-Paclitaxel In mPDAC
2015-11-23
2018-12-27
Completed
76
A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma
2017-01-13
2023-07-26
Active, not recruiting
514
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
2017-01-10
2022-12-20
Completed
772
A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)
2017-09-22
2024-04-27
Recruiting
1,000
A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)
2017-10-13
2025-02-08
Recruiting
410
A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer
2018-01-11
2024-01-31
Recruiting
572
A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma
2018-03-15
2022-11-17
Completed
558
A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)
2018-04-24
2025-01-19
Active, not recruiting
453
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "Hospital Universitari Vall dHebron; Oncology" #1 sponsor was "Hoffmann-La Roche" with 16 trials, followed by "EMD Serono Research & Development Institute, Inc." with 8 trials
sponsored, "Pfizer" with 2 trials sponsored, "Genentech, Inc." with 1 trials sponsored and "Merck KGaA, Darmstadt, Germany"
with 1 trials sponsored. Other sponsors include -5 different institutions and
companies that sponsored additional 5 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "Hospital Universitari Vall dHebron; Oncology"
#1 collaborator was "Merck KGaA, Darmstadt, Germany" with 8 trials as a collaborator, "BioLineRx, Ltd." with 1 trials as a collaborator, "Celgene" with 1 trials as a collaborator, "Halozyme Therapeutics" with 1 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were
collaborators in the rest 5 trials.
Clinical Trials Conditions at Hospital Universitari Vall dHebron; Oncology
According to Clinical.Site data, the most researched conditions in "Hospital Universitari Vall dHebron; Oncology" are
"Non-small Cell Lung Cancer" (5 trials), "Biliary Tract Cancer" (4 trials), "Carcinoma, Hepatocellular" (2 trials), "Cholangiocarcinoma" (2 trials) and "Gallbladder Cancer" (2 trials). Many other conditions were trialed in "Hospital Universitari Vall dHebron; Oncology" in a lesser frequency.
Clinical Trials Intervention Types at Hospital Universitari Vall dHebron; Oncology
Most popular intervention types in "Hospital Universitari Vall dHebron; Oncology" are "Drug" (28 trials), "Other" (3 trials), "Radiation" (3 trials) and "Biological" (1 trials). Other intervention types were less common.
The name of intervention was led by "Atezolizumab" (13 trials), "Cisplatin" (9 trials), "Carboplatin" (7 trials), "Gemcitabine" (7 trials) and "Placebo" (7 trials). Other intervention names were less common.
Clinical Trials Genders at Hospital Universitari Vall dHebron; Oncology
The vast majority of trials in "Hospital Universitari Vall dHebron; Oncology" are
24 trials for "All" genders, 3 trials for "Female" genders and 1 trials for "Male" genders.
Clinical Trials Status at Hospital Universitari Vall dHebron; Oncology
Currently, there are NaN active trials in "Hospital Universitari Vall dHebron; Oncology".
undefined are not yet recruiting,
6 are recruiting,
10 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 11 completed trials in Hospital Universitari Vall dHebron; Oncology,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in Hospital Universitari Vall dHebron; Oncology, 7 "Phase 1"
clinical trials were conducted, 12 "Phase 2" clinical
trials and 13 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 0 trials, and there were
also 0 trials that are defined as “Not Applicable".